Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 5 Threshold leves and Corresponding value based price of Sorafenib

From: A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer

Willingness to pay Threshold

20,000

40,000

60,000

>100,00 (102,616)

Cost of sorafenib arm

10620 (CI 95% 9022.0-12490.0)

13760 (CI 95% 11680.0-16290.0)

16996 (CI 95%14370.0-20120.0)

23806 (CI 95% 20,000 -28220)

Cost of bsc arm

7336.0 (CI 95%: 6327.0- 8468.0).

7336.0 (CI 95%: 6327.0- 8468.0).

7336.0 (CI 95%: 6327.0- 8468.0).

7336.0 (CI 95%: 6327.0- 8468.0).

Incremental QALY gains

0,1605 QALY

0,1605 QALY

0,1605 QALY

0,1605 QALY

Incremental cost

3284

6424

9630

16470

VBP of sorafenib

810

1325

1816

2880